Targeting Inflammatory and Oxidative Pathways in Idiopathic Pulmonary Fibrosis: Synergistic Effects of Quercetin and Pirfenidone in Modulating Nrf2/PPAR-γ and TLR-4/NF-κB Pathways - PubMed
4 days ago
- #Pulmonary Fibrosis
- #Pirfenidone
- #Quercetin
- Pulmonary fibrosis (PF) is a progressive condition marked by inflammation and excessive fibrous tissue formation.
- Pirfenidone, an FDA-approved drug, slows PF progression by reducing TGF-β production and exhibiting antioxidant effects.
- Quercetin (Quer) shows promise in PF management due to its anti-inflammatory, antioxidant properties, and ability to inhibit collagen synthesis.
- The study explores the combined therapeutic potential of Pirfenidone and Quercetin in mitigating bleomycin-induced lung fibrosis in vivo.
- Bleomycin (BLM) exposure upregulates inflammatory markers and oxidative stress while reducing antioxidant defenses.
- Pirfenidone moderately decreases fibrotic changes, whereas Quercetin shows a stronger reduction in oxidative and inflammatory parameters.
- BLM increases NF-κB, PI3K, TLR-4, and MAPK expression, which are significantly reduced by Pirfenidone and Quercetin.
- PPAR-γ mRNA levels, reduced by BLM, are increased by both Pirfenidone and Quercetin.
- Combined administration of Pirfenidone and Quercetin provides a synergistic effect, more effectively alleviating BLM-induced lung fibrosis than either drug alone.
- The study suggests that the combination therapy could enhance anti-fibrotic treatments and warrants further clinical investigation.